Recipharm

GenIbet offers cGMP manufacturing excellence and a comprehensive service that encompasses cell line development, process and analytical development and cGMP production of recombinant proteins, DNA, Viral and Cell products. This, combined with in-house fill and finish capabilities, gives our clients the opportunity to go from bench to clinic in one facility. GenIbet leverages its activities on the extensive expertise in molecular biology, virology, microbial and cell culture of our partner and main shareholder, iBET (Instituto de Biologia Experimental e Tecnológica).

Sanofi - business is inhalation contract manufacturing business.

Kemwell’s pharmaceutical businesses

Cirrus was founded in 1997 and is based in the Research Triangle Park, NC. We are registered with the U.S. Food & Drug Administration (FDA) as a cGMP Analytical Testing Facility. A combination of our scientific expertise and timely delivery of quality services have resulted in a high rate of customer satisfaction. We collaborate with companies across the globe, providing full product development as well as task-based services. Our scientists offer proven expertise in all dosage forms, including inhaled, nasal, oral, parenteral, and topical & transdermal. Cirrus understands our quality services are directly related to the project results you want to achieve. With this in mind, our processes are designed to ensure budgets and timelines are met and that we provide the overall value to exceed your expectations.

Kemwell provides customized process/ product development and manufacturing solutions to pharmaceutical and biopharmaceutical organizations.

In 1981 the manufatoring process was moved into the the production plant which was owned by the Moroni family in the year 1969. in 1982, pursuing a far-sighted industrial policy, the Company decided to build a new and advanced production plant where the present head office in Brescia now resides. The production plant has been constantly improved over the years with the creation of new manufacturing, services and research areas in order to cope with the increased production requirements and higher standards of quality.

Nitin Lifesciences Limited is an Indian pharmaceutical company that specializes in the manufacturing of injectable drug products. Founded in 1994 and based in Karnal, India, it operates three WHO-GMP certified plants, including one in an excise-free zone in Paonta Sahib, Himachal Pradesh. The company produces a diverse range of products such as liquid ampoules, liquid vials, dry powders (both beta-lactam and non-beta-lactam), eye and ear drops, and lyophilized vials. Nitin Lifesciences offers over 200 formulations across various therapeutic areas, including antibiotics, analgesics, antiarthritics, antidiabetics, and anti-inflammatory medications, among others. Additionally, it provides contract manufacturing services to major Indian pharmaceutical companies, enhancing their production capacities. The company serves clients both domestically and internationally, and also supplies medicines for relief efforts by non-profit organizations.

OnTarget Chemistry is specialized in medicinal chemistry offering synthesis and analytical services.

Flamel Technologies SA is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs. Flamel currently markets three previously Unapproved Marketed Drugs ("UMDs") in the United States, Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection), and Akovaz™ (ephedrine sulfate injection). The Company also develops products utilizing its proprietary drug delivery platforms, Micropump® (oral sustained release microparticles platform), along with its tangent technologies, LiquiTime® (a Micropump-derivative platform for liquid oral products) and Trigger Lock™ (a Micropump-derivative platform for abuse-resistant opioids). Additionally, the Company has developed a long acting injectable platform, Medusa™, a hydrogel depot technology, particularly suited to the development of subcutaneously administered formulations. Current applications of Flamel's drug delivery products include sodium oxybate (Micropump®), extended-release of liquid medicines such as ibuprofen and guaifenesin (LiquiTime®, through a license arrangement with Elan Pharma International Limited for the U.S. Over-the-Counter market) and a current study of the delivery of exenatide utilizing the Medusa™ technology.

It might be simplistically stated that Lusomedicamenta is specialised in the manufacture of pharmaceutical products: solids, liquids and semi-solids. It might the be added the the company is focused on new products carrying out the management of the entire process under a key-in-hand system from product creation the the registration dossier. It would also be no exaggeration to declare that, and without ever deviating on the highest of quality standard, Lusomedicamenta produces over 150 formulas and cover 700 formats, exporting its products to over 45 countries worldwide. Each and every on of these statements, remais correct but still fails to define us. We are defined by our staff. Competent, highly qualified people, motivaded by innovative and future oriented projects and more than able to manage scope for expansion through competitive cost, swift creative processes and a pragmatic, flexible, innovative and creative vision. These are, unquestionably, the core competences ans assets that ensure the sastisfaction and confidence of our clients wich have enabled Lusomedicamenta to establish its position as a leading benchmark for the pharmaceutical sector.

Corvette Group Pharmaceutical Services S.p.A. is the Parent Company of firms operating as suppliers of high value added services for the pharmaceutical industry. Corvette Group is controlled by LBO Italia Investimenti S.p.A. , an industrial, long-term private equity Holding firm with the objective of developing its subsidiaries in accordance with the highest level of ethical and professional standards. It supports the development plans of its subsidiaries in financial terms, by providing them capital, and in industrial and managerial terms, with its highly professional management structure. In addition to its managers, who own a significant share of the capital, LBO’s shareholders include important International investors like financial institutions, family offices and qualified entrepreneurs.

Cobra Biomanufacturing operates as a contract manufacturer of biopharmaceuticals.

AstraZeneca Biotech Laboratory engages in research of proteins produced by disease genes. The company is based in Södertälje, Sweden. As of January 1, 2009, AstraZeneca Biotech Laboratory operates as a subsidiary of Recipharm AB.